Glass House Brands Inc.
GLASFNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for GLASF. That does not mean none is planned.
Get an email about GLASF's next catalysts
Track Glass House Brands (GLASF) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Simvastatin | Phase 2 | Alzheimer's Disease | - | - |
Frequently asked questions
What is in Glass House Brands Inc.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in Glass House Brands Inc.'s (GLASF) pipeline across Phase 2. Its lead program is Simvastatin (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Glass House Brands Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Glass House Brands Inc. (GLASF) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track GLASF biotech catalysts?β
Add GLASF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Glass House Brands Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
